Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee

October 9, 2003




AM Session





  1. Frost, B-M. Pharmacokinetics of Doxorubicin in Children With Acute Lymphoblastic Leukemia: Multi-Institutional Collaborative Study. Med Pediatr Oncol. 2002; 38:329-337.


  1. Groninger, E, et al. Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia. Ped Rsch. 2002;2(1):113-118.


  1. Hempel, G, Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Canc Chemother and Pharm. 2001


  1. Nath, CE. Population pharmacokinetics of amphotericin B in children with malignant diseases. J Clin Pharmacol. 2001; 52:671-680.



PM Session


  1. Pawar, S. and Kumar, A. Issues in the Formulation of Drugs for Oral Use in Children Role of Excipients. Pediatr Drugs. 2002; 4(6):371-379.


  1. Nahata, MC. Pediatric Drug Formulations: Challenges and Potential Solutions. Annals of Pharmacother. Feb 1999; 33:247-249.


  1. Kovarik, JM, Clinical Development of an Everolimus Pediatric Formulation: Relative Bioavailability, Food Effect, and Steady-State Pharmacokinetics. J Clin Pharmacol. 2003;43:141-147.